A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily). The study vaccine (HyperAcute®-Melanoma) is made from three types of human melanoma cell lines (grown in the laboratory) in which the genes have been slightly changed. This clinical study will try to discover the safety of the study vaccine combined with PEG-Intron®, its side effects and the potential benefits, if any.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

NCT00861406

Melanoma

COMPLETED PHASE1

Vaccine Treatment for Advanced Malignant Melanoma

NCT00300612

Malignant Melanoma

COMPLETED PHASE1/PHASE2

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

NCT03897881

Melanoma

ACTIVE_NOT_RECRUITING PHASE2

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

NCT00613509

Melanoma Cancer

TERMINATED PHASE2

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

NCT00005949

Recurrent Melanoma Stage IV Melanoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will look at the anti-tumor vaccine effect, side effects and toxicity of the HyperAcute® Vaccine with PEG-Intron®. It is hoped that the immune system's response to these genetically engineered melanoma cells and PEG-Intron® will cause a reaction that will make it react to and attack and kill the melanoma cells and keep it from growing, possibly causing the tumors to shrink.

Patients that are eligible are 19 years or older and have been diagnosed with advanced, treatment resistant or recurrent melanoma, an aggressive usually pigmented form of skin cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HyperAcute vaccine

1.8 mL weekly

Intervention Type BIOLOGICAL

Pegylated Interferon-Alpha 2b

6.0 mcg/kg weekly

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PEG-Intron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 19 years or older
* Histological diagnosis of melanoma
* AJCC Stage IIIC (any T, N1b, N2b, N3, M0) or Stage IV (any T, and N, M1), metastatic, progressive, refractory, recurrent or high risk of recurrence melanoma.
* Expected survival of more than 6 months
* Adequate organ function
* Measurable or non-measurable disease
* Must have negative serologies for Hepatitis B and C and HIV prior to entering study
* Must be more than 4 weeks since major surgery, radiotherapy, chemotherapy or biotherapy/targeted therapies
* Male and female subjects of child producing potential must agree to use contraception or avoidance pregnancy measures while enrolled on the study and for one month after the last immunization.

Exclusion Criteria

* Active CNS metastases or carcinomatous meningitis
* Hypercalcemia
* Pregnant or nursing women
* Other malignancy within five years
* History of organ transplant or current active immunosuppressive therapy
* Subjects taking systemic corticosteroid therapy
* Active infection or antibiotics within 1-week prior to study
* Uncontrolled or significant congestive heart failure, myocardial infarction, ventricular arrhythmias or pulmonary dysfunction
* Autoimmune disease
* A known allergy to any component of the HyperAcute vaccine or PEG-Intron
* Patients having undergone splenectomy
* Patients with sickle-cell anemia or thalassemia major.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No